Zinc and Iron Absorption From Common Beans in Young Adult Women

NCT ID: NCT06327529

Last Updated: 2025-11-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-05-01

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Fifteen female study participants will be enrolled in a randomized crossover study to measure fractional and total zinc and iron absorption from four common bean (Phaseolus vulgaris) varieties with varying phytate and polyphenolic contents. Phytate, the storage form of phosphorus in plants, and polyphenols, which contribute to the varied colors of common beans, are natural components of the beans and can reduce zinc and iron bioavailability from these foods.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Each participant will attend a total of 10 study visits. The first visit will be a screening visit to determine eligibility, and will include the administration of health history and food frequency questionnaires, and a urine pregnancy test. Participant will also be given a ASA24 24-hour dietary recall at visit 1 to return at visit 2. All subsequent visits (2 through 10) will begin with a blood sample (15 mL, or 1 tablespoon, after a 12 hour overnight fast).

Visit 2 will establish the baseline distribution of naturally occurring zinc and iron isotopes in the blood, and will include the administration of water enriched in zinc of a specific naturally-occurring isotopic mass (zinc-68, 4 mg).

Visits 2-5 will be on consecutive days, while Visit 6 will be 14 days following Visit 5. Visits 3 and 4 will include breakfast, lunch, and dinner, each containing a small serving of beans that are enriched in specific isotopic masses of iron and zinc (2 mg each of zinc-67 and iron-57, or 1 mg each of zinc-70 and iron-58). Visits 5 and 6 are for blood sampling, to measure the zinc in blood plasma (Visit 5) and the iron that has reached a 14-day equilibrium in red blood cells (Visit 6). Participants will also be given a ASA24 24-hour dietary recall at visit 6 to return at visit 7.

Visits 6-9 will be on consecutive days, starting 28 days (the approximate length of one menstrual cycle) after Visit 3, while Visit 10 will be 14 days following Visit 9. The 28-day timing is needed to minimize the potential influence of natural variation in circulating hormones, on zinc metabolism. A second urine pregnancy test will be administered on Visit 10, to detect any pregnancies that would have occurred at the time of the study meals 2 weeks prior or earlier. Participants will also be given a ASA24 dietary recall at visit 9 to return at visit 10.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Zinc Absorption Iron Absorption

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

zinc iron absorption phytate polyphenols beans

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

A four arm multi-tracer non-randomized crossover design
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants
Study participants will be masked to the type of bean that they will be receiving.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Bean Variety 1

Enriched with Zinc-67, Iron-57

Group Type EXPERIMENTAL

SER 118

Intervention Type OTHER

Bean High in Phytic Acid and High in Inhibitory Polyphenols

Bean Variety 2

Enriched with Zinc-70, Iron-58

Group Type EXPERIMENTAL

LMP 1001

Intervention Type OTHER

Bean Low in Phytic Acid and High in Inhibitory Polyphenols

Bean Variety 3

Enriched with Zinc-67, Iron-57

Group Type EXPERIMENTAL

LPA 586

Intervention Type OTHER

Bean Low in Phytic Acid and Low in Inhibitory Polyphenols

Bean Variety 4

Enriched with Zinc-70, Iron-58

Group Type EXPERIMENTAL

KAT B1

Intervention Type OTHER

Bean High in Phytic Acid and Low in Inhibitory Polyphenols

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SER 118

Bean High in Phytic Acid and High in Inhibitory Polyphenols

Intervention Type OTHER

LMP 1001

Bean Low in Phytic Acid and High in Inhibitory Polyphenols

Intervention Type OTHER

LPA 586

Bean Low in Phytic Acid and Low in Inhibitory Polyphenols

Intervention Type OTHER

KAT B1

Bean High in Phytic Acid and Low in Inhibitory Polyphenols

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy eumenorrheic (regular monthly menstrual cycles of 25-30-days in length)
* BMI 18.5 - 30 kg/m2
* Regular consumer of beans, i.e. ≥ 4 servings per month
* Usual iron intake estimated by Food Frequency Questionnaire to be less than the Recommended Daily Allowance (RDA) of 18 mg/d (8)
* Subject is willing and able to comply with the study protocols.
* Subject is willing to participate in all study procedures.

Exclusion Criteria

* Dislike or allergy to beans
* Self-reported current or recent pregnancy (within the past 12 months)
* Self-reported recent termination of pregnancy (3 months if abortion in 1st or 2nd trimester, or 12 months if in 3rd trimester)
* Self-reported plans to become pregnant during the study period
* Self-reported cancer
* Self-reported surgery without the past 12 months
* Currently taking prescription drugs, other than for contraception, or any nutritional supplements
* Any daily iron supplementation within the past 12 months.
* Currently breastfeeding
* Any medical conditions affecting iron or zinc metabolism (such as hemochromatosis or sickle cell disease)
Minimum Eligible Age

19 Years

Maximum Eligible Age

24 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of California, Davis

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Andrew G Hall, PhD

Role: PRINCIPAL_INVESTIGATOR

University of California, Davis

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Nutrition

Davis, California, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Roberta R Holt, PhD

Role: CONTACT

Phone: 530-400-5952

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Roberta R Holt, PhD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2101814

Identifier Type: -

Identifier Source: org_study_id